Speciality: Nephrology
Description:
A warm welcome to all the medical professionals in this interesting session on Holistic CRM Care : Optimizing Kidney Protection with SLGT2-inhibitor
Holistic care in chronic kidney disease (CKD) management emphasizes kidney protection alongside overall patient well-being, with SGLT2 inhibitors playing a pivotal role. These drugs not only slow CKD progression but also address comorbidities like heart failure and diabetes, reducing hospitalization risks and enhancing quality of life. Their ability to lower albuminuria and improve glycemic control aligns with a patient-centered approach to renal care.
In optimizing kidney protection, SGLT2 inhibitors exemplify the integration of evidence-based medicine into holistic care strategies. By targeting metabolic and hemodynamic pathways, they provide multifaceted benefits, including cardiovascular risk reduction. This comprehensive approach enables healthcare providers to improve outcomes in CKD patients while addressing interconnected health challenges.
Therefore, get an overall knowledge of Holistic CRM Care : Optimizing Kidney Protection with SLGT2-inhibitor. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions
See More Webinars @ Hidoc Webinars
1.
Advances in "next generation" photoactive cancer therapy
2.
Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL
3.
The American College of Physicians updated its recommendations for colorectal cancer screening.
4.
Optimizing Sequencing of BCMA-Directed Therapies in Myeloma
5.
According to a study, patients with ovarian cancer who undergo aggressive surgery have a 70% lower chance of dying.
1.
Quality of Life Using Precision Functional Recovery After Organ-Preserving Interventions
2.
Cancer Memory: A Persistent Threat to Tumor Recurrence and Metastasis
3.
Neoadjuvant Abraxane Chemotherapy Combined with Neutrophil Cytopharmaceuticals and Radiotherapy
4.
Modern Developments in Oncology for Specialists
5.
Can We Repurpose BV-CHP for Better Outcomes in Peripheral T-Cell Lymphoma?
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
2.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
3.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
4.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
5.
Navigating the Complexities of Ph Negative ALL - Part XII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation